US FDA accelerates psychedelic drug approvals amid Trump directive, foregrounding corporate mental health commodification over systemic care
Original framing: “US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive” — South China Morning Post
Psychedelics were criminalized in the 20th century largely due to political and racial motivations, not scientific evidence, with Nixon’s War on Drugs targeting counterculture movements. The current resurgence mirrors earlier cycles of psychedelic research in the 1950s-60s, which were abruptly halted by stigma and prohibition. This historical pattern reveals how drug policies are often shaped by power structures rather than public health needs.
The FDA’s accelerated review of psychedelic drugs under Trump’s directive exemplifies how neoliberal policies prioritize corporate profit over public health, while erasing Indigenous and marginalized knowledge systems that have long used these substances responsibly.
This approach mirrors historical patterns of drug criminalization and resurgence, where power structures shape policy to serve elite interests rather than community needs. The current model risks repeating past mistakes by reducing psychedelics to patentable commodities, ignoring their cultural and spiritual significance, and failing to address the structural failures of mental healthcare. A systemic solution requires decolonizing research, integrating therapies into public systems, and reforming drug policy to center equity and accessibility. Without these changes, the psychedelic renaissance may become another chapter in the exploitation of marginalized communities and the commodification of healing.